Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Exelixis Inc (EXEL)  
$21.74 0.19 (0.87%) as of 4:30 Tue 6/4


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 310,240,000
Market Cap: 6.74(B)
Last Volume: 1,506,385 Avg Vol: 2,434,266
52 Week Range: $18.78 - $24.13
Level I Sector: Industrials
Level II Sector: Diversified Services
Level III Sector: Research Services

Member Indexes:

    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:

     
Insider 3 Months    : 17.5
Insider 6 Months    : 18.9
Insider 3/6 Months : 36.8
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Exelixis is an oncology-focused biotechnology company that engages in the discovery, development and commercialization of new medicines for cancers. Co.'s products include: CABOMETYX® (cabozantinib) tablets approved for renal cell carcinoma, and for previously treated hepatocellular carcinoma; and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other products are: COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 425,000 615,000 735,409 735,409
Total Buy Value $8,733,955 $12,666,689 $15,268,727 $15,268,727
Total People Bought 1 1 1 1
Total Buy Transactions 2 3 4 4
Total Shares Sold 80,531 216,700 593,372 1,012,962
Total Sell Value $1,755,807 $4,825,489 $12,725,795 $20,083,859
Total People Sold 5 7 9 12
Total Sell Transactions 5 9 16 27
End Date 2024-03-07 2023-12-05 2023-06-06 2022-06-06

   
Records found: 1437
  Page 10 of 58  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Lamb Peter EVP, Scientific Strategy & CSO   •       –      –    2021-11-15 4 OE $6.21 $294,975 D/D 47,500 458,740     -
   Morrissey Michael M President and CEO   •       •      –    2021-11-15 4 D $18.10 $3,507,418 D/D (193,780) 367,288     -
   Hessekiel Jeffrey EVP and General Counsel   •       –      –    2021-11-01 4 AS $22.03 $112,728 D/D (5,117) 632,825 -6%     
   Morrissey Michael M President and CEO   •       •      –    2021-10-22 4 D $21.33 $527,854 D/D (24,747) 561,068     -
   Morrissey Michael M President and CEO   •       •      –    2021-10-22 4 A $0.00 $0 D/D 94,002 585,815     -
   Hessekiel Jeffrey EVP and General Counsel   •       –      –    2021-10-15 4 AS $22.02 $283,684 D/D (12,883) 637,942 -6%     
   Lamb Peter EVP, Scientific Strategy & CSO   •       –      –    2021-10-15 4 AS $21.92 $1,041,200 D/D (47,500) 411,240 -6%     
   Lamb Peter EVP, Scientific Strategy & CSO   •       –      –    2021-10-15 4 OE $6.21 $294,975 D/D 47,500 458,740     -
   Lamb Peter EVP, Scientific Strategy & CSO   •       –      –    2021-09-30 4 D $20.63 $148,062 D/D (7,177) 411,240     -
   Lamb Peter EVP, Scientific Strategy & CSO   •       –      –    2021-09-30 4 A $0.00 $0 D/D 28,950 418,417     -
   Hessekiel Jeffrey EVP and General Counsel   •       –      –    2021-09-30 4 D $20.63 $156,644 D/D (7,593) 650,825     -
   Hessekiel Jeffrey EVP and General Counsel   •       –      –    2021-09-30 4 A $0.00 $0 D/D 28,950 658,418     -
   Senner Christopher J. EVP and CFO   •       –      –    2021-09-30 4 D $20.63 $176,861 D/D (8,573) 415,528     -
   Senner Christopher J. EVP and CFO   •       –      –    2021-09-30 4 A $0.00 $0 D/D 32,567 424,101     -
   Haley Patrick J. EVP, Commercial   •       –      –    2021-09-30 4 D $20.63 $111,732 D/D (5,416) 304,528     -
   Haley Patrick J. EVP, Commercial   •       –      –    2021-09-30 4 A $0.00 $0 D/D 28,950 309,944     -
   Senner Christopher J. EVP and CFO   •       –      –    2021-09-21 4 D $20.33 $1,119,309 D/D (55,057) 391,534     -
   Senner Christopher J. EVP and CFO   •       –      –    2021-09-21 4 OE $3.66 $329,400 D/D 90,000 446,591     -
   Haley Patrick J. EVP, Commercial   •       –      –    2021-09-16 4 AS $20.36 $509,000 D/D (25,000) 280,994 -15%     
   Haley Patrick J. EVP, Commercial   •       –      –    2021-09-16 4 OE $1.70 $42,500 D/D 25,000 305,994     -
   Lamb Peter EVP, Scientific Strategy & CSO   •       –      –    2021-09-15 4 AS $20.46 $971,850 D/D (47,500) 389,467 -12%     
   Lamb Peter EVP, Scientific Strategy & CSO   •       –      –    2021-09-15 4 OE $6.21 $294,975 D/D 47,500 436,967     -
   Lamb Peter EVP, Scientific Strategy & CSO   •       –      –    2021-08-16 4 AS $18.44 $1,014,200 D/D (55,000) 389,467 3%     
   Lamb Peter EVP, Scientific Strategy & CSO   •       –      –    2021-08-16 4 OE $1.90 $104,500 D/D 55,000 444,467     -
   Schwab Gisela Md Pres, Prod Dev & Med Aff & CMO   •       –      –    2021-07-26 4 OE $4.20 $168,000 D/D 40,000 689,078     -

  1437 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 10 of 58
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed